Tegafur/Uracil

替加氟/尿嘧啶

Report date: 2024/12/27 11:44:02

Base Information

Drug NameTegafur/Uracil
Drug Alias NameTegafur-Uracil二氧嘧啶/替加氟Tegafur and Uracil尿嘧啶/替加氟Uracil/Tegafur +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThymidylate synthase inhibitorsDihydropyrimidine dehydrogenase inhibitors
TargetsThymidylate synthaseDihydropyrimidine dehydrogenase
Therapy Area/IndicationsHead and Neck NeoplasmsStomach NeoplasmsRectal Neoplasms +[6] 
Global Approved IndicationsNeoplasms
Approved Indications in ChinaNeoplasms
Original Approved Country/TerritoryJapan
Original Approved DateN/A
Country/TerritoryTaiwanFranceEU +[5] 
CombinationsYes TegafurUracil
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaiho Pharmaceutical Co LtdTianjin Taihe Pharmaceutical Co Ltd
Inactive CompaniesMackay Memorial Hospital IncInstitut De Cancerologie De L OuestTokyo Medical And Dental University +[5] 
Active IndicationsNeoplasms
Inactive IndicationsHead and Neck NeoplasmsStomach NeoplasmsRectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG